- Home
- / AVEO Pharmaceuticals
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
AVEO Pharmaceuticals financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$15
2023-01-20
Market Capitalization
$515.6 M
2023-01-20
Revenue
$42.3 M
FY, 2021
CreditSafe Score
?
Score changed on Jun 07, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 164.8M | 19.3M | 1.3M | 18.1M | 19.0M | 2.5M | 7.6M | 5.4M | 28.8M | 6.0M | 42.3M |
| Revenue growth, % | 1301.6% | ||||||||||
| Cost of goods sold | 4.7M | ||||||||||
| General and administrative expense | 29.2M | 36.9M | 28.7M | 18.6M | 14.2M | 8.2M | 9.1M | 10.8M | 11.2M | 22.2M | 60.8M |
| Operating expense total | 130.9M | 128.3M | 97.2M | 56.8M | 27.1M | 31.9M | 34.3M | 31.4M | 29.2M | 44.9M | 87.1M |
| EBIT | 33.9M | (111.6M) | (103.9M) | (50.4M) | (12.4M) | (29.4M) | (28.8M) | (25.4M) | (374.0K) | (38.9M) | (49.6M) |
| EBIT margin, % | 20.6% | -578.8% | -8035.9% | -278.4% | -65.3% | -1168.7% | -380.1% | -468.8% | -1.3% | -645.9% | |
| Interest income | 527.0K | 497.0K | 125.0K | 32.0K | 21.0K | 58.0K | |||||
| Interest expense | 3.8M | 3.5M | (4.0M) | ||||||||
| Pre tax profit | 30.6M | (26.8M) | (64.9M) | (5.3M) | 9.4M | (35.6M) | |||||
| Income tax expense | 101.0K | 101.0K | |||||||||
| Net Income | 30.6M | (114.4M) | (107.0M) | (52.7M) | (15.0M) | (26.9M) | (65.0M) | (5.3M) | 9.4M | (35.6M) | (53.3M) |